Unveiling the potential of HBK-15 as a dual-action drug candidate for mood and cognition restoration in mouse depression model
Kinga Sałaciak, Klaudia Lustyk, Karolina Pytka · FENS Forum 2024
Depression, affecting 280 million people worldwide, is marked by a significant treatment gap. Current therapies with delayed onset of action fail to alleviate the symptoms in almost half of patients, often neglecting the cognitive deficits. This highlights the critical need for fast-acting antidepressants with memory-enhancing properties. HBK-15, a multimodal compound, previously demonstrated antidepressant-, anxiolytic-like and antiamnesic effects in rodents. Our study aimed to explore HBK-15's potential in reversing stress-induced behavioral abnormalities and elucidating its underlying mecha
ePoster · Neuroscience